Clinical Trial Update: 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Triapine (3-AP) and fludarabine in various myeloproliferative disorders and advanced phases of chronic myeloid leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Chronic Myeloid Leukemia Bcr-abl1 Negative
• Chronic Myeloid Leukemia Accelerated Phase
• Chronic Myeloid Leukemia Blast Crisis
• Eosinophilic Leukemia
• Essential Thrombocythemia
• Myelofibrosis
• Myelomonocytic Leukemia
• Polycythemia Vera

Drugs mentioned

• Fludarabine (Fludarabine)
• Triapine (Triapine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 2 | Status: COMPLETED | Results posted: 2014-05-21